Cempra Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Cempra Inc |
Stock Symbol : | NASDAQ: CEMP |
Class Period Start: | 05/01/2016 |
Class Period End: | 11/01/2016 |
Lead Plaintiff motion: | 01/03/2017 |
Date Filed: | 11/04/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Middle District of North Carolina |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the January 3, 2017 lead plaintiff deadline in a class action lawsuit filed against Cempra Inc (NASDAQ: CEMP) (“Cempra” or “the Company”). The suit is pending in the U.S. District Court for the Middle District of North Carolina and investors, who purchased Cempra Inc securities between May 1, 2016 and November 1, 2016, have until January 3, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Cempra Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that one of Cempra's lead product candidates, solithromycin, posed significant safety risks for hepatotoxicity. On November 2, 2016, the U.S. Food and Drug Administration reported its preliminary review of Cempra's drug, solithromycin, used for the treatment of community-acquired bacterial pneumonia and specified a significant safety signal for hepatotoxicity. FDA reviewers noted that "a significant safety signal for hepatotoxicity was observed in the solithromycin development program," and there was concern for "the high rate of infusion site-related reactions." On this news, NASDAQ: CEMP fell $9.71 per share or over 58% to $6.95 on November 2, 2016. If you were negatively impacted by your investment in Cempra Inc securities between May 1, 2016 and November 1, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |